Brief Report - (2025) Volume 10, Issue 6
Received: 01-Dec-2025, Manuscript No. jomp-26-185131;
Editor assigned: 03-Dec-2025, Pre QC No. P-185131;
Reviewed: 17-Dec-2025, QC No. Q-185131;
Revised: 22-Dec-2025, Manuscript No. R-185131;
Published:
29-Dec-2025
, DOI: 10.37421/2576-3857.2025.10.333
Citation: Al-Harthi, Mohammed. ”Tumor Microenvironment’s Role in Colorectal Cancer Progression.” J Oncol Med and Pract 10 (2025):333.
Copyright: © 2025 Al-Harthi M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
The tumor microenvironment (TME) in colorectal cancer (CRC) is a dynamic and intricate ecosystem where tumor cells engage in complex interactions with various stromal components, profoundly influencing disease progression and therapeutic responses. Among these stromal elements, cancer-associated fibroblasts (CAFs) stand out as major orchestrators of the tumor microenvironment, actively promoting CRC growth, invasion, metastasis, and resistance to therapy through the secretion of numerous factors and direct cell-cell interactions [1].
These reprogrammed fibroblasts arise from activated fibroblasts and exhibit diverse phenotypes, contributing to the remodeling of the surrounding tissue by secreting growth factors, cytokines, and extracellular matrix (ECM) components [2].
Within this complex milieu, the immune landscape plays a critical role, with tumor-associated macrophages (TAMs) being abundant and exhibiting diverse polarization states that can either promote or suppress anti-tumor immunity, alongside other immune cells like T cells and B cells [3].
The extracellular matrix itself is not merely a passive scaffold but a dynamic signaling platform that influences cell migration, proliferation, and survival, with its dysregulated deposition and degradation, often mediated by enzymes like matrix metalloproteinases (MMPs), contributing to increased tumor stiffness and enhanced invasion [4].
Furthermore, the hypoxic nature of many solid tumors, including CRC, profoundly impacts the TME by triggering adaptive responses that promote angiogenesis, metabolic reprogramming, invasion, and immune evasion, largely mediated by hypoxia-inducible factors (HIFs) [5].
Tumor cells actively communicate with these stromal cells through various paracrine signaling pathways, secreting cytokines, chemokines, and growth factors that shape the TME, recruit and activate CAFs and immune cells, and ultimately support tumor growth and angiogenesis [6].
The metabolic reprogramming of stromal cells, particularly CAFs, significantly impacts the TME and CRC progression, as CAFs can alter their metabolic pathways to support tumor growth through nutrient sharing and the production of crucial metabolites [7].
The ECM's role extends beyond structural support; its compositional and structural changes, driven by enzymes like MMPs and lysyl oxidases (LOXs), impact tumor cell behavior and the recruitment of stromal cells, with increased ECM stiffness promoting cancer cell invasion and metastasis [8].
The intricate crosstalk between tumor cells and the immune microenvironment also involves regulatory T cells (Tregs), which are key immunosuppressive populations within the CRC TME that can suppress anti-tumor immune responses, often being recruited and supported by tumor cells [9].
Finally, the interplay between tumor cells and mesenchymal stem cells (MSCs) within the CRC microenvironment contributes to tumor progression, metastasis, and therapeutic resistance, as MSCs can be reprogrammed into cancer-associated mesenchymal cells that promote tumor growth and angiogenesis [10].
The tumor microenvironment in colorectal cancer (CRC) is characterized by a complex interplay between malignant cells and a supportive stromal network, significantly influencing the disease's trajectory and response to treatment. Cancer-associated fibroblasts (CAFs) are pivotal stromal components that actively foster CRC progression by secreting a wide array of factors that promote tumor growth, invasion, and resistance to therapy. These fibroblasts originate from activated fibroblasts and can adopt diverse phenotypes, leading to the remodeling of the tumor's physical and biochemical environment through the release of growth factors, cytokines, and extracellular matrix (ECM) components [1].
The composition of the immune infiltrate within the CRC TME is highly heterogeneous and critically determines tumor progression and the efficacy of immunotherapies. Tumor-associated macrophages (TAMs), a prominent immune cell type in CRC, can exist in various polarization states, with M2-like TAMs generally promoting tumor progression and immune suppression, while M1-like TAMs may exert anti-tumor effects [3].
The extracellular matrix (ECM) plays a dynamic role beyond structural support, acting as a signaling platform that modulates cancer cell behavior, including migration, proliferation, and survival. Aberrant ECM deposition and degradation, often orchestrated by enzymes such as matrix metalloproteinases (MMPs), contribute to increased tumor stiffness, enhanced invasiveness, and the establishment of pre-metastatic niches, thereby facilitating CRC metastasis [4].
Hypoxia, a prevalent feature in solid tumors like CRC, profoundly affects the TME and tumor-stroma interactions. Low oxygen levels induce adaptive responses in both tumor and stromal cells, promoting angiogenesis, metabolic shifts, invasion, and immune evasion, with hypoxia-inducible factors (HIFs) serving as key mediators of these adaptations and driving a more aggressive and treatment-resistant tumor phenotype [5].
Tumor cells engage in extensive bidirectional communication with stromal cells through paracrine signaling pathways, releasing cytokines, chemokines, and growth factors that are essential for shaping the TME, promoting tumor cell proliferation, survival, and migration. This crosstalk enables tumor-derived factors to recruit and activate CAFs and immune cells, which, in turn, provide factors that sustain tumor growth and angiogenesis [6].
Metabolic reprogramming within stromal cells, particularly CAFs, significantly influences the TME and CRC progression. CAFs can modify their metabolic activities to sustain tumor growth by sharing nutrients and producing metabolites that fuel cancer cells, thereby enhancing tumor cell proliferation, survival, and therapeutic resistance. This metabolic cross-talk can also impact the availability of nutrients and oxygen, further shaping the tumor ecosystem [7].
The ECM is an active contributor to CRC progression and tumor-stroma interactions. Alterations in ECM composition and structure, driven by enzymes like MMPs and lysyl oxidases (LOXs), influence tumor cell behavior and the recruitment of stromal cells. Increased ECM stiffness, a common characteristic of CRC, can promote cancer cell invasion and metastasis by activating mechanosensitive signaling pathways, suggesting that targeting ECM components or remodeling enzymes could be a viable therapeutic strategy [8].
The interaction between tumor cells and the immune microenvironment is a critical determinant of CRC progression and response to immunotherapy. Regulatory T cells (Tregs) represent a significant immunosuppressive population within the CRC TME, often enriched in proximity to the tumor. Tregs suppress anti-tumor immunity by inhibiting effector immune cells, and tumor cells can enhance Treg recruitment and function through various signaling molecules, creating an immunosuppressive environment conducive to tumor growth and immune evasion [9].
Furthermore, the interaction between tumor cells and mesenchymal stem cells (MSCs) within the CRC microenvironment contributes to tumor progression, metastasis, and therapeutic resistance. MSCs, upon recruitment to the tumor site, can be reprogrammed by tumor cells into cancer-associated mesenchymal cells (CAMs) that actively promote tumor growth, angiogenesis, immune suppression, and the formation of pre-metastatic niches [10].
Colorectal cancer (CRC) progression is heavily influenced by the complex interactions within its tumor microenvironment. Cancer-associated fibroblasts (CAFs) are key players, promoting tumor growth and therapeutic resistance. The immune landscape, including tumor-associated macrophages and T cells, exhibits diverse functions impacting tumor fate. The extracellular matrix (ECM) provides structural support and signaling cues, with its remodeling contributing to invasion and metastasis. Hypoxia drives adaptive responses, fostering an aggressive and resistant tumor phenotype. Tumor cells communicate with stromal cells via paracrine signaling, recruiting and activating supportive cells. Stromal cell metabolic reprogramming, especially in CAFs, fuels tumor growth. ECM stiffness and changes mediated by enzymes like MMPs promote metastasis. Regulatory T cells within the immune microenvironment suppress anti-tumor immunity, aiding tumor evasion. Mesenchymal stem cells can be reprogrammed into supportive cells, contributing to tumor progression and resistance. Targeting these intricate tumor-stroma dialogues is crucial for developing effective CRC therapies.
None
None
Journal of Oncology Medicine & Practice received 142 citations as per Google Scholar report
